{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicj5r6n2qkzogflso3t6mdt663mkfdd3crkn2paqxwlnwyvg5qzku",
    "uri": "at://did:plc:wvq6whvtae6lnllryphpwbhg/app.bsky.feed.post/3meemco24iko2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidcmxyarhzpatpve4mgsk5mwkpd6237wlopiqywf32ejc7fa5itwq"
    },
    "mimeType": "image/png",
    "size": 18055
  },
  "description": "Headline: J&J exited 2025 with broad-based momentum (despite a large Stelara headwind), guided to ~$100B+ 2026 revenue, and reiterated line-of-sight to double-digit growth by the back half of the decade—supported by oncology/immunology launches, MedTech acceleration, and continued portfolio reshaping (Ortho separation).\n\n\nKey Metrics\n\n * Q4 worldwide sales: $24.6B (+7.1% operational).\n * FY2025 worldwide sales: $94.2B (+5.3% operational).\n * Q4 GAAP net earnings / EPS: $5.1B; $2.10 (vs $1.41 pri",
  "path": "/johnson-johnson-jnj-q4-2025-earnings-core-brief-edition/",
  "publishedAt": "2026-02-08T18:55:32.000Z",
  "site": "https://www.core-brief.com",
  "textContent": "**Headline:** J&J exited 2025 with broad-based momentum (despite a large Stelara headwind), guided to **~$100B+** 2026 revenue, and reiterated line-of-sight to **double-digit** growth by the back half of the decade—supported by oncology/immunology launches, MedTech acceleration, and continued portfolio reshaping (Ortho separation).\n\n### Key Metrics\n\n  * **Q4 worldwide sales:** **$24.6B** (**+7.1%** operational).\n  * **FY2025 worldwide sales:** **$94.2B** (**+5.3%** operational).\n  * **Q4 GAAP net earnings / EPS:** **$5.1B** ; **$2.10** (vs **$1.41** prior year).\n  * **Q4 adj. net earnings / adj. EPS:** **$6.0B** ; **$2.46** (**+21.5%** / **+20.6%** YoY).\n  * **FY2025 GAAP EPS:** **$13.00** (included **$7.0B** talc reserve reversal in Q1).\n  * **FY2025 adj. net earnings / adj. EPS:** **$26.2B** ; **$10.79** (**+8.1%** YoY).\n  * **FY2025 free cash flow:** **$19.7B** ; **FY2026 FCF outlook:** **~$21B**.\n  * **Cash / debt (end-2025):** **~$20B** cash & marketable securities; **$48B** debt; **~$28B** net debt.\n  * **Q4 segment sales:** Innovative Medicine **$15.8B** (**+7.9%** op); MedTech **$8.8B** (**+5.8%** op).\n  * **Adjusted income before tax margin (enterprise, Q4):** **28.7%** (vs **24.1%** prior year).\n\n\n\n### Segment & Strategy Highlights\n\n**Innovative Medicine (Q4 sales: $15.8B, +7.9% op)**\n\n  * **Oncology** : Strong multiple myeloma franchise.\n    * **Darzalex:** **+24.1%** (share gains + market growth).\n    * **Carvykti:** **$555M** , **+63.2%** (share gains + expansion); **> 10,000** patients treated across **14** markets (management cited).\n    * **Rybrevant + Lazcluze:** **$216M** , **+76.5%** (launch uptake; share gains in 1L/2L).\n  * **Immunology** :\n    * **Tremfya:** **+65.4%** ; management: **> $5B** FY sales for first time and targets **> $10B** peak.\n    * **Stelara:** **-48.6%** (biosimilar competition + Part D redesign).\n    * Upcoming: **icotrokinra / “icotide”** (oral IL-23) anticipated US approval/launch in **2026** (psoriasis first; IBD later).\n  * **Neuroscience** :\n    * **Spravato:** **+67.8%** (strong demand).\n    * **Caplyta:** **$249M** in Q4 (acquired via Intracellular); cited highest-ever new patient starts post-MDD approval.\n\n\n\n**MedTech (Q4 sales: $8.8B, +5.8% op)**\n\n  * **Cardiovascular** :\n    * **Abiomed:** **+18.3%** (Impella adoption).\n    * **Shockwave:** **+22.9%** (coronary + peripheral adoption); became **13th** billion-dollar MedTech platform.\n    * EP/PFA: Q4 EP growth cited at **+6.5%** overall; leadership push with **Varipulse** and pipeline cadence (new catheter “every year” through decade end; **~40,000** AF patients treated with Varipulse cited).\n  * **Surgery:** **+3.7%** (headwinds: competition; China VBP; portfolio actions). Highlighted Ethicon **4000** stapler launch; **Ottava** de novo FDA submission.\n  * **Vision:** Contact lenses & surgical vision solid.\n    * Contact lens/other products: **+5.3%** (category growth + price actions).\n    * Surgical vision: **+10.8%** (premium IOL demand; Technis Odyssey momentum; planned US launch of **Technis PureSee** in 2026).\n\n\n\n**Portfolio / Capital deployment**\n\n  * Continued transformation toward “higher-growth, higher-margin” markets; Ortho separation targeted **mid-2027**.\n  * 2025 investment cited as “over” a large amount (exact figure not clearly stated) including acquisitions (Intracellular, Haldor Therapeutics) + US manufacturing buildout.\n\n\n\n### Product, Tech, AI / Devices (if discussed)\n\n  * **Anexo** (bladder cancer drug-device system): initial FDA approval (Sept); positive early launch commentary; permanent **J-code** expected **early Q2 (April)**.\n  * Platform expansion: **TAR-210** (erlotinib payload device) targeting intermediate-risk; management cited **> 90%** CR rates (as discussed on the call).\n  * **Robotics** : **Monarch** urology robotics; **Ottava** robot via de novo pathway (no predicate device claimed).\n\n\n\n### Credit & Risk (only if applicable)\n\n  * **Talc litigation:** Management addressed Daubert/Special Master report; plans to appeal portions; reiterated intent to litigate aggressively and said it doesn’t change strategy (no reserve change guidance provided).\n\n\n\n### Balance Sheet & Capital\n\n  * **End-2025:** **~$20B** cash & marketable securities; **$48B** debt; **~$28B** net debt.\n  * **FY2025 FCF:** **$19.7B** ; **FY2026 FCF outlook:** **~$21B**.\n  * Share count: diluted share count expected **~2.44B** in 2026; **~$0.05** EPS headwind vs 2025 due to dilution mechanics (as described).\n\n\n\n### Guidance / Outlook\n\n  * **FY2026 operational sales growth:** **5.7%–6.7%** (midpoint **~$100B** , **+6.2%**).\n    * Acquisitions: **~+30 bps** tailwind to operational growth (midpoint adjusted operational growth **~5.9%**).\n    * **53rd week** : adds **~100 bps** benefit.\n  * **FY2026 reported sales growth:** **6.2%–7.2%** (midpoint **$100.5B** , **+6.7%**) based on stated FX methodology.\n  * **FY2026 adj. pre-tax operating margin:** improvement of **≥50 bps** (includes **~$500M** MedTech tariffs; includes impact of voluntary US government agreement to improve access/lower costs).\n  * **Net interest expense:** **$300M–$400M**.\n  * **Net other income:** **$1.0B–$1.2B**.\n  * **Effective tax rate:** **17.5%–18.5%**.\n  * **FY2026 adj. EPS:** **$11.28–$11.48** (midpoint growth **~+5.5%**).\n    * Reported adj. EPS midpoint: **$11.53** (includes **+$0.15** FX benefit per management).\n\n\n\n### Bottom Line\n\nJ&J is framing 2025 as the “catapult” year: core Innovative Medicine brands (notably oncology and Tremfya) are scaling fast enough to offset Stelara erosion, while MedTech is leaning into CV/EP momentum, surgical robotics (Ottava), and premium vision. Guidance implies another solid year with **≥50 bps** margin expansion despite **~$500M** MedTech tariff headwinds, and management is leaning hard on a pipeline/launch cadence that supports **double-digit** growth aspirations later in the decade.\n\n* * *",
  "title": "Johnson & Johnson (JNJ) Q4 2025 Earnings — Core Brief Edition",
  "updatedAt": "2026-02-08T18:55:32.000Z"
}